Scientific Knowledge

Leadgene's glycerol-free series products provides flexibility for various conditions and are compatible with LEADSPHERE™ Lyophilization Technology.

Leadgene offers about two hundreds RUO-grade biosimilar antibodies.

The Omicron differs structurally from all other variants that have been known, and compared to the wild-type Wuhan-Hu-1 strain, 32 out of 50 mutations are located on the spike protein.

Multiple research teams recently proposed another unique feature of the Omicron: the variant prefers entering cells by an endosomal route, similar to SARS-CoV, rather than driving receptor-dependent syncytium formation, catalyzed by surface TMPRSS2 protease.

Compatible with Leadsphere® Lyophilization Technology for a lyophilized format (glycerol-free)

It is imperative to explore and develop more efficient and comprehensive methods to further improve drug development processes and address the challenges posed by increasingly complex diseases.

During the past few decades, numerous efforts have been devoted to the field of immunotherapy to improve the efficacy and safety of conventional therapies, such as radiation and chemotherapy.

A study carried out by Leadgene Biomedical first identified the antibodies against ACE2 in COVID-19 patients, and then found a positive correlation between the amounts of antibodies against ACE2 and S1-RBD.

Let Leadgene Biomedical’s COVID-19 series products become your comprehensive solutions!

The scientists reported a new approach that utilizes injectable hydrogels to deliver CAR-T cells together with cytokines.